EPHA published a position paper on medicine shortages in Europe. EHA welcomes its  recommendations to address the increasing shortages crisis, which threatens patient outcomes and patient safety.

The 4^th EHA-ISHBT Hematology Tutorial on Hematological Disorders was held on February 28 and 29 in Chandigarh, India, and chaired by Prof John Gribben, Prof Neelam Varma and Prof Pankaj Malhotra.

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases. View the EHA methodology for guidelines, EHA Guidelines by topic and Guidelines produced by other societies and endorsed by EHA

As COVID19 progresses limited information is available in hematology to manage patient care during the pandemic. The EHA Scientific Working Group Infections in Hematology has developed key questions and answers to stand by hematology professionals in the COVID19 crisis.

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

I was nominated to be on the EHA Ballot in 2000 and to my surprise and happiness, I was elected as Councilor. I became President-elect in 2003 and was the EHA President 2005-2007.

Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?

While health policy remains the primary responsibility of Member States, in many areas the added value of EU-level collaboration and harmonization has increased. EU initiatives in health have shown a mixed record in terms of impact, but hopes are high for the latest one, the ambitious Europe’s Beating Cancer Plan.

I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on Granulocytes &...

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

November 22-24, 2019 |Madrid, Spain

For the second time the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron joined in the organization of the meeting focused on Red...

Clinical trials and drug development have become more complex over the years. One complicating factor is the increased administrative burden, as was pointed out in the previous edition of HemAffairs. Doctors and clinical researchers are more and more bound to rules they deem neither necessary nor effective. At first sight, the requirements for clinical trials seem clear and thorough. Nonetheless, the interpretation and implementation of these rules leave room for improvement.

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis. EU legislation has been in place for over 15 years to regulate those practices, and to ensure safety and quality standards for substances of human origin (SoHO). For instance, through technical and traceability requirements for BTC, the reporting of serious adverse reactions (SARs), and verification procedures for imported BTC.

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).